Skip to main content
Caplight Logo









Syneron Bio

Syneron Bio

Private
BeijingHealthcare & Life Scienceshttps://syneronbio.com/

Last Round

Series B

Mar 31, 2026

Total Funding Raised

$250M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Syneron Bio is a biotechnology company that has developed an AI-powered platform, Synova, for the discovery and development of macrocyclic peptide therapeutics targeting oncology, autoimmune, metabolic, and rare diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Medical AI, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Infrastructure

Keywords

macrocyclic peptidesdrug discovery platformAI drug discoverybiotech platformpeptide therapeuticsin silico drug designpeptide-drug conjugatescell-penetrant peptidesundruggable targetsbiopharma R&Dgenerative biologyAI-native biotechdrug discovery engineclosed-loop discoverybiotech licensing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Syneron Bio Comparables

Compare Syneron Bio with similar companies based on industry and business-model similarity.

Syneron Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Unnatural Products
87%
Vilya
86%
Orbis Medicines
85%

Syneron Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BMar 31, 2026
Series ADec 18, 2025

Syneron Bio Investors

Notable investors and investment history

Syneron Bio investors
InvestorRounds
KHK & PartnersSeries A
BioTrack CapitalSeries B
SV Health InvestorsSeries B
Hillhouse InvestmentSeries B, Series A
True Light CapitalSeries B
联想创投集团 (Lenovo Capital and Incubator Group)Series B, Series A
CICC CapitalSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 31, 2026

    $150M round raised.

  • Dec 18, 2025

    $100M round raised.

Syneron Bio Filings

Explore SEC and related filing metadata, where available.

Syneron Bio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Syneron Bio's valuation, stock price, and market status.

Is Syneron Bio a public or private company?

Syneron Bio is a private company.

What is the current stock price of Syneron Bio?

Syneron Bio is a private company with no public stock price. No recent secondary market data is available.

How much is Syneron Bio worth (valuation)?

Valuation information for Syneron Bio is not publicly available.

Can I buy Syneron Bio stock?

Syneron Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Syneron Bio's last funding round?

Syneron Bio's most recent funding round was Series B on March 31, 2026.

Who are the main investors in Syneron Bio?

Key investors in Syneron Bio include CICC Capital, CDH VGC, Pfizer, CDH Investments, Decheng Capital.

Will Syneron Bio IPO soon?

No public IPO plans have been announced for Syneron Bio.

How can I track Syneron Bio secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Syneron Bio's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersBeijing
Employee Range13
Year Founded2022
Last FundingMar 31, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?